Lars Fruergaard Jørgensen, Novo Nordisk CEO (Ludovic Marin/ Pool Photo via AP)
May 2, 2024 04:55 AM EDTUpdated 07:06 AM
Pharma

No­vo’s GLP-1 sales boost prof­its, yet full po­ten­tial still curbed by sup­ply squeeze

Ayisha Sharma

News Reporter

Anna Brown

News Reporter

No­vo Nordisk is still hit­ting a glass ceil­ing in rev­enues due to GLP-1 sup­ply con­straints even as sales keep ris­ing. The price of We­govy dropped …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times